Introduction
============

*Pseudomonas aeruginosa* is one of the most frequent and severe causes of hospital-acquired infections, particularly affecting immunocompromised (especially neutropenic) and Intensive Care Unit (ICU) patients. Indeed, *P. aeruginosa* is the first cause of ventilator associated pneumonia (VAP) and burn wound infections, both associated with a very high mortality rate ([@B72]; [@B4]). Likewise, *P. aeruginosa* is the most frequent driver of chronic respiratory infections in cystic fibrosis (CF) patients or other chronic underlying diseases ([@B20]).

One of the most striking features of *P. aeruginosa* is its outstanding capacity for developing antimicrobial resistance to nearly all available antipseudomonal agents through the selection of chromosomal mutations. Indeed, treatment failure caused by the development of antimicrobial resistance is a too frequent outcome of *P. aeruginosa* infections. The problem of mutation-mediated antibiotic resistance is further amplified in the chronic infection setting, due to the very high prevalence of hypermutable strains, showing greatly enhanced spontaneous mutation rates caused by defective DNA repair or error avoidance systems ([@B62]; [@B52]).

Beyond the obvious negative impact of resistance development for the treated patient, the accumulation of several of these chromosomal mutations leads to the emergence of multidrug resistant (MDR), extensively drug-resistant (XDR) or even pan-antibiotic-resistant (PDR) strains, which can be responsible for notable epidemics in the hospital setting ([@B18]; [@B70]). Moreover, recent studies have evidenced the existence of MDR/XDR global clones disseminated in different hospitals worldwide, and for that reason they have been denominated high-risk clones ([@B73]; [@B63]). Although high-risk clones are frequently associated with transferable antimicrobial resistance determinants, they also typically show a wide range of chromosomal mutations playing a major role in the resistance phenotype ([@B63]). Likewise, recent reports have evidenced the interpatient spread of antimicrobial resistance mutations linked to the transmission of epidemic CF strains ([@B51]).

Along with growing information from mechanistic studies on chromosomal resistance mechanisms and their complex regulatory pathways, involved in adaptive resistance ([@B49]; [@B59]; [@B69]; [@B41]), the introduction of whole-genome sequencing (WGS) approaches is shaping up a new dimension for the mutational resistance landscape. The term resistome was first used to account for the set of primary antibiotic resistance genes that could be eventually transferred to human pathogens ([@B16]). Soon after the concept of intrinsic resistome was introduced to include all chromosomal genes that are involved in intrinsic resistance, and whose presence in strains of a bacterial species is independent of previous antibiotic exposure and is not due to horizontal gene transfer (HGT) ([@B24]). Finally, the term mutational resistome was more recently implemented to account for the set of mutations involved in the modulation of antibiotic resistance levels in the absence of HGT ([@B10]; [@B51]). Recent WGS data obtained from *in vitro* assays on the evolution of antibiotic resistance, *in vivo* monitoring of antimicrobial resistance development, analysis of sequential CF isolates, and characterization of wide spread epidemic high-risk clones provide new insights into the evolutionary dynamics and mechanisms of *P. aeruginosa* antibiotic resistance ([@B9]; [@B25]; [@B17]; [@B36]; [@B51]). Indeed, the analysis of WGS mutational resistomes has proven to be useful for understanding the evolutionary dynamics of classical resistance mechanisms and to depict new ones for the majority of antimicrobial classes, including β-lactams, aminoglycosides, fluoroquinolones, polymixins and others, as reviewed in the following sections. **Table [1](#T1){ref-type="table"}** summarizes the main genes and mutations known to increase resistance levels and therefore shaping up the *P. aeruginosa* mutational resistome.

###### 

Main genes and mutations known to be involved in increased *P. aeruginosa* antibiotic resistance.

  Gene       Resistance mechanisms/altered target   Antibiotics affected^a^            Type of mutation   Relevant examples of gain-of-function mutations                                      Reference
  ---------- -------------------------------------- ---------------------------------- ------------------ ------------------------------------------------------------------------------------ ---------------------------------------
  *gyrA*     DNA gyrase                             FQ                                 Gain-of-function   G81D, T83A, T83I, Y86N, D87G, D87N, D87Y, Q106L                                      [@B7]; [@B44]; [@B10]; [@B17]; [@B51]
  *gyrB*     DNA gyrase                             FQ                                 Gain-of-function   S466F, S466Y, Q467R, E468D                                                           [@B7]; [@B44]; [@B17]; [@B51]
  *parC*     DNA topoisomerase IV                   FQ                                 Gain-of-function   S87L, S87W                                                                           [@B7]; [@B44]; [@B10]; [@B17]
  *parE*     DNA topoisomerase IV                   FQ                                 Gain-of-function   S457G, S457T, E459D, E459K                                                           [@B7]; [@B44]; [@B17]; [@B51]
  *pmrA*     Lipopolysaccharide (lipid A)           COL                                Gain-of-function   L157Q                                                                                [@B47]
  *pmrB*     Lipopolysaccharide (lipid A)           COL                                Gain-of-function   L14P, A54V, R79H, R135Q, A247T, A248T, A248V, R259H, M292I, M292T                    [@B3]; [@B56]
  *phoQ*     Lipopolysaccharide (lipid A)           COL                                Loss-of-function                                                                                        
  *parR*     Lipopolysaccharide (lipid A)           COL                                Gain-of-function   M59I, E156K                                                                          [@B59]; [@B30]
             OprD downregulation                    IMP, MER                                                                                                                                   
             MexEF-OprN hyperproduction             FQ                                                                                                                                         
             MexXY-OprM hyperproduction             FQ, AMG, CEF                                                                                                                               
  *parS*     Lipopolysaccharide (lipid A)           COL                                Gain-of-function   L14Q, V101M, L137P, A138T, A168V Q232E, G361R                                        [@B59]; [@B26]; [@B30]
             OprD downregulation                    IMP, MER                                                                                                                                   
             MexEF-OprN hyperproduction             FQ                                                                                                                                         
             MexXY-OprM hyperproduction             FQ, AMG, CEF                                                                                                                               
  *cprS*     Lipopolysaccharide (lipid A)           COL                                Gain-of-function   R241C                                                                                [@B31]
  *colR*     Lipopolysaccharide (lipid A)           COL                                Gain-of-function   D32N                                                                                 [@B31]
  *colS*     Lipopolysaccharide (lipid A)           COL                                Gain-of-function   A106V                                                                                [@B31]
  *mexR*     MexAB-OprM hyperproduction             FQ, CAZ, CEF, PPT, MER, CAZ/AVI    Loss-of-function                                                                                        
  *nalC*     MexAB-OprM hyperproduction             FQ, CAZ, CEF, PPT, MER, CAZ/AVI    Loss-of-function                                                                                        
  *nalD*     MexAB-OprM hyperproduction             FQ, CAZ, CEF, PPT, MER, CAZ/AVI    Loss-of-function                                                                                        
  *nfxB*     MexCD-OprJ hyperproduction             FQ, CEF                            Loss-of-function                                                                                        
  *mexS*     MexEF-OprN hyperproduction             FQ                                 Loss-of-function                                                                                        
             OprD downregulation                    IMP, MER                                                                                                                                   
  *mexT*     MexEF-OprN hyperproduction             FQ                                 Gain-of-function   G257S, G257A                                                                         [@B42]
             OprD downregulation                    IMP, MER                                                                                                                                   
  *cmrA*     MexEF-OprN hyperproduction             MER, FQ                            Gain-of-function   A68V, L89Q, H204L, N214K                                                             [@B43]
  *mvaT*     MexEF-OprN hyperproduction             FQ                                 Loss-of-function                                                                                        
  *PA3271*   MexEF-OprN hyperproduction             FQ                                 Loss-of-function                                                                                        
  *mexZ*     MexXY-OprM hyperproduction             FQ, AMG, CEF                       Loss-of-function                                                                                        
  PA5471.1   MexXY-OprM hyperproduction             FQ, AMG, CEF                       Loss-of-function                                                                                        
  *amgS*     MexXY-OprM hyperproduction             FQ, AMG, CEF                       Gain-of-function   V121G, R182C                                                                         [@B46]
  *oprD*     OprD inactivation                      IMP, MER                           Loss-of-function                                                                                        
  *ampC*     AmpC structural modification           CAZ/AVI, C/T                       Gain-of-function   T96I, G183D, E247K                                                                   [@B8]; [@B27]
  *ampD*     AmpC hyperproduction                   CAZ, CEF, PPT                      Loss-of-function                                                                                        
  *ampDh2*   AmpC hyperproduction                   CAZ, CEF, PPT                      Loss-of-function                                                                                        
  *ampDh3*   AmpC hyperproduction                   CAZ, CEF, PPT                      Loss-of-function                                                                                        
  *ampR*     AmpC hyperproduction                   CAZ, CEF, PPT                      Gain-of-function   D135N, G154R                                                                         [@B2]; [@B10]
  *dacB*     AmpC hyperproduction                   CAZ, CEF, PPT                      Loss-of-function                                                                                        
  *ftsI*     Penicillin-binding-protein 3 (PBP3)    CAZ, CEF, PPT, MER, CAZ/AVI, C/T   Gain-of-function   R504C, R504H, P527T, F533L                                                           [@B19]; [@B9],[@B10]; [@B17]; [@B51]
  *fusA1*    Elongation factor G                    AMG                                Gain-of-function   I61M, V93A, E100G, K504E, Y552C, P554L, A555E, N592I, P618L, T671A, T671I            [@B25]; [@B6]; [@B17]; [@B51], [@B50]
  *glpT*     Transporter protein GlpT               FOS                                Loss-of-function                                                                                        
  *rpoB*     RNA polymerase β-chain                 RIF                                Gain-of-function   S517F, Q518R, Q518L, D521G, H531Y, H531L, S536F, L538I, S579F, S579Y, N629S, D636Y   [@B37]

a

FQs, fluoroquinolones; COL, colistin; AMGs, aminoglycosides; CAZ, ceftazidime; CEF, cefepime; PPT, piperacillin-tazobactam; IMP, imipenem; MER, meropenem; CAZ/AVI, ceftazidime/avibactam; C/T, ceftolozane/tazobactam; FOS, fosfomycin; RIF, rifampicin

.

β-Lactam Mutational Resistome
=============================

The most frequent mutation-driven β-lactam resistance mechanism is likely the overproduction of the chromosomal cephalosporinase AmpC, involving a wide range of genes belonging to complex regulatory pathways of cell-wall recycling ([@B41]). Among them, the mutational inactivation of *dacB*, encoding the non-essential penicillin-binding protein (PBP) PBP4, and *ampD*, encoding a *N*-acetyl-muramyl-[L]{.smallcaps}-alanine amidase have been found to be the most frequent cause of *ampC* derepression and β-lactam resistance ([@B40]; [@B57]). The inactivation of PBP4 has also been shown to activate the BlrAB/CreBC regulatory system, further increasing resistance levels ([@B57]). Additionally, specific point mutations leading to a conformation change in the transcriptional regulator AmpR, causing *ampC* upregulation and β-lactam resistance, have been noted among clinical strains. They include the D135N mutation, described in several species besides *P. aeruginosa*, including *Stenotrophomonas maltophilia*, *Citrobacter freundii*, or *Enterobacter cloacae* ([@B41]) or the R154H mutation, linked to the widespread MDR/XDR ST175 high-risk clone. Mutation of many other genes, including those encoding other amidases (AmpDh2 and AmpDh3), other PBPs (such as PBP5 and PBP7), lytic transglycosylases (such as SltB1 and mltB), MPL (UDP-*N*-acetylmuramate:Lalanyl-γ-[D]{.smallcaps}-glutamyl-meso-diaminopimelate ligase), or NuoN (NADH dehydrogenase I chain N) have been shown to enhance *ampC* expression, either alone or combined with other mutations, although their impact on β-lactam resistance among clinical strains still needs to be further analyzed ([@B41]).

In addition to *ampC* overexpression, recent studies have revealed that β-lactam resistance development, including the novel combinations of β-lactam-β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam, may result from mutations leading to the structural modification of AmpC ([@B8]; [@B45]; [@B27]; [@B32]). Likewise, recent studies identified diverse AmpC variants associated with high-level cephalosporin resistance, including ceftolozane/tazobactam and ceftazidime/avibactam, in a small proportion (around 1%) of clinical *P. aeruginosa* isolates ([@B5]). Over 200 Pseudomonas Derived Cephalosporinase (PDC) variants have been described so far, including those associated with enhanced ceftolozane/tazobactam and ceftazidime/avibactam resistance (**Table [1](#T1){ref-type="table"}**). An update database of PDC variants is maintained in our laboratory and is freely available at <https://arpbigidisba.com>. Additionally, resistance development to ceftolozane/tazobactam and/or ceftazidime/avibactam may involve mutations leading to the structural modification of narrow spectrum OXA-2 and OXA-10 acquired oxacillinases ([@B27],[@B28]).

Besides β-lactamases, there is increasing evidence on the role of target modification in *P. aeruginosa* β-lactam resistance. Particularly noteworthy are the mutations in *ftsI*, encoding PBP3, an essential high molecular class B PBP with transpeptidase activity ([@B14]). Indeed, data from CF patients ([@B19]; [@B51]), epidemic high-risk clones ([@B10]; [@B17]) as well as from *in vitro* studies ([@B9]) have recently shown that PBP3 is under strong mutational pressure, and that specific mutations in this PBP contribute to β-lactam resistance development. R504C/H and F533L mutations are likely those most commonly reported, and are located within the protein domains implicated in the formation and stabilization of the inactivating complex β-lactam-PBP3 ([@B33]). Moreover, these specific mutations have been documented to emerge *in vivo* during chronic respiratory infection in CF patients ([@B19]; [@B51]) and upon meropenem ([@B9]) and aztreonam ([@B39]) exposure *in vitro*. However, the precise contribution of PBP3 mutations to β-lactam resistance phenotypes needs to be further investigated using isogenic strains. Likewise, despite unique polymorphisms have also been detected in some clinical strains for other PBPs, their role in β-lactam resistance, if any, still needs to be experimentally addressed.

Other relevant components of the β-lactam mutational resistome are the porins and RND efflux pumps. Mutational inactivation of OprD is well-known to be the primary carbapenem resistance mechanisms in *P. aeruginosa* ([@B49]; [@B13]). OprD inactivation typically results from indels or nonsense mutations, including the Q142X mutation, characteristic of the widespread ST175 high-risk clone ([@B10]). Additionally, some amino acid substitutions have also been recently associated with OprD-driven resistance, particularly in the CF setting ([@B66]). Finally, carbapenem resistance may also result from *oprD* repression caused by mutations in the MexEF-OprN efflux pump regulators (*mexS/T*) or the ParRS two-component system ([@B48]). Overexpression of MexAB-OprM, caused by mutation of several genes involved in its regulation (*mexR*, *nalC*, or *nalD*) increases MICs of most β-lactams except imipenem, whereas overexpression of MexXY (*mexZ*, *parSR*, *amgS* mutations) is particularly involved in cefepime resistance ([@B48]). Additionally, sequence variations in unique residues are detected in the genes coding for the efflux pump ([@B17]; [@B51]); however, their contribution to resistance profiles, if any, still needs to be further explored.

Finally, another potentially relevant mutational β-lactam resistance mechanism is the selection of large (\>200 kb) deletions affecting specific parts of the chromosome ([@B9]). Although the basis of the conferred resistance phenotype still needs to be further clarified, these mutants can be recognized by the characteristic brown pigment (pyomelanine) caused by the deletion of one of the affected genes, *hmgA*, coding for a homogentisate-1,2- dioxygenase. This type of deletion has been documented in both, *in vitro* evolved β-lactam-resistant mutants and CF isolates ([@B9]; [@B34]). However, the deletion of *hmgA* is not responsible for the resistance phenotype, which could be linked to the deletion of another of the affected genes, *galU*. This gene codes for a UDP-glucose pyrophosphorylase involved in the synthesis of the lipopolysaccharide (LPS) core. Indeed, analysis of transposon mutant libraries has shown that inactivation of *galU* increases ceftazidime and meropenem MICs ([@B21]; [@B1]).

Aminoglycoside Mutational Resistome
===================================

In the absence of horizontally-acquired aminoglycoside modifying enzymes, resistance to this antibiotic class has been particularly linked to the mutational overexpression of MexXY-OprM. Indeed, mutational overexpression of this pump, mainly caused by *mexZ*, *amgS*, or *parRS* mutations (**Table [1](#T1){ref-type="table"}**), is very frequent among clinical isolates, from both, CF patients and nosocomial infections ([@B30]; [@B65]). Moreover, recent studies show that the epidemic high-risk clone ST175 overexpresses MexXY due to a specific mutation in *mexZ* (G195E) ([@B10]). However, recent studies have revealed that the aminoglycoside mutational resistome extends far beyond MexXY overexpression, and that high-level resistance may result from the accumulation of multiple mutations, and the involvement of several novel resistance determinants has been recently documented ([@B23]; [@B68]; [@B25]). Among them is particularly noteworthy *fusA1*, coding for the elongation factor G. Indeed, specific FusA1 mutations have been associated with aminoglycoside resistance *in vitro* ([@B25]; [@B50]) and among clinical, particularly CF, strains ([@B15]; [@B53]; [@B29]; [@B51], [@B50]). Moreover, the implication of *fusA1* mutations in aminoglycoside resistance has been recently confirmed through site-directed mutagenesis ([@B6]).

Fluoroquinolone Mutational Resistome
====================================

The fluoroquinolone mutational resistome generally includes specific missense mutations in DNA gyrase (*gyrA* and/or *gyrB*) and topisomerase IV (*parC* and/or *parE*) Quinolone Resistance-Determining Regions (QRDRs) (**Table [1](#T1){ref-type="table"}**) ([@B7]; [@B44]). High-level fluoroquinolone resistance in *P. aeruginosa* high-risk clones is nearly universal, and typically involves combinations of mutations in GyrA-T83 and ParC-S87 ([@B17]). QRDR mutations involved in fluoroquinolone resistance in CF might be more variable ([@B51]). It is also well-known that the mutational overexpression of efflux pumps modulate fluoroquinolone resistance (**Table [1](#T1){ref-type="table"}**). While the overexpression of MexAB-OprM and MexXY-OprM is globally more frequent among clinical strains, its contribution to clinical fluoroquinolone resistance is likely more modest ([@B7]). On the other hand, the mutational overexpression of MexEF-OprN or MexCD-OprJ is associated with high-level (clinical) fluoroquinolone resistance, and although their prevalence is considered low except in the CF chronic infection setting, recent data show that it might be higher than expected ([@B66]).

Polymixin Mutational Resistome
==============================

Whereas the prevalence of polymyxin (colistin and polymyxin B) resistance is still globally low (\<5%), it has increased in the last years because of the frequent use of these last-resource antibiotics for the treatment of MDR/XDR nosocomial and CF strains. Polymyxin resistance results most frequently from the modification of the LPS caused by the addition of a 4-amino-4-deoxy-[L]{.smallcaps}-arabinose moiety in the lipid A structure ([@B61]; [@B38]). The involved mutations are frequently located in the PmrAB or PhoPQ two-component regulators, which lead to the activation of the *arnBCADTEF* operon ([@B3]). More recent studies have revealed that mutations in the ParRS two-component regulator, not only produce polymyxin resistance due to the activation of the *arnBCADTEF* operon, but also lead to a MDR phenotype determined by the overprexpression of MexXY and the repression of OprD ([@B59]). Moreover, two additional two-component regulators, ColRS and CprRS, have been recently found to be involved in polymyxin resistance ([@B31]). The analysis of colistin resistance mechanisms among clinical strains is not always straight forward, since the presence of mutations in these two-component regulators is not always associated with clinical colistin resistance, probably denoting partial complementation between the different regulators ([@B56]; [@B31]; [@B51]). Moreover, recent *in vitro* evolution assays have revealed the implication of additional mutations in high level colistin resistance, facilitated by the emergence of mutator (*mutS* deficient) phenotypes ([@B22]). Particularly noteworthy among them are those occurring in LptD, LpxC, or MigA.

Other Antibiotics
=================

Even if not considered a classical antipseudomonal agent, fosfomycin has emerged in the last decade as a potentially useful antibiotic in urinary tract infections and combined therapy for MDR/XDR *P. aeruginosa* ([@B54]). However, fosfomycin resistance spontaneous mutation rates are high and the mechanism involved is typically the mutational inactivation of *glpT*, coding for a glycerol-3-phospate permease required for fosfomycin uptake ([@B12]; [@B67]). *glpT* mutations, conferring high-level fosfomycin resistance are also frequently found among MDR/XDR high-risk clones ([@B17]), and some specific mutations, such as T211P, have been fixed in some widespread lineages as described for ST175 ([@B10]). Another potentially useful antimicrobial for combined therapy against MDR/XDR *P. aeruginosa* is rifampicin ([@B11]). However, rifampicin resistance may emerge at high frequency due to the selection of specific missense mutations in *rpoB*, coding for the beta subunit of the RNA polymerase ([@B37]). Another example of newer antibiotic families with antipseudomonal activity are the pacidamycins, uridyl peptide antibiotics, targeting translocase I, an essential enzyme in peptidoglycan biosynthesis ([@B55]). Emergence of high-level resistance to this antibiotic class has been shown to involve the selection of mutations in the Opp transporter, a binding protein-dependent ABC transporter used for oligopeptide import. Finally, the *P. aeruginosa* mutational resistome, particularly in the CF setting, may also include resistance to other used antibiotics such as the frequent mutations of domain V of 23S rRNA, conferring macrolide resistance ([@B60]).

Concluding Remarks and Future Perspectives
==========================================

The analysis of the *P. aeruginosa* mutational resistome, together with the analysis of the horizontally-acquired resistance determinants, should be useful for establishing the antibiotic resistance genotype, which should correlate with the antibiotic resistance phenotype and as such, it should permit the design of therapeutic strategies and for monitoring the efficacy of administered antibiotic treatments. However, the current applicability of the analysis of the mutational resistome is still limited by the large number of genes involved and the complexity of the resistance phenotypes generated, and, particularly, by the difficulties, in many cases, for differentiating relevant mutations from simple natural polymorphisms. Obviously, the evolution of the mutational resistome is a direct consequence of antimicrobial exposure and as such, it is not surprising that exposure to one antibiotic drives evolution of the mutational resistome for that antibiotic. However, the complexity of the actual resistance profile is further increased by the specificity and interactions among different resistance mechanisms. Indeed, a resistance mutation selected by one antibiotic may have a variable effect among the different agents within the same antibiotic class or family. Likewise, cross resistance (or collateral resistance) implies that exposure to one antibiotic drives also the development of resistance to a different one from the same or other classes. Typically, this is caused by the developed resistance mechanism (such as efflux pump overexpression) affecting simultaneously different antibiotics. Indeed, potential development of cross resistance is a major issue to consider when using antibiotic combinations ([@B71]). Moreover, cross resistance between antibiotics and antiseptics and other biocides may also occur ([@B48]). Perhaps less obvious is collateral susceptibility, which implies that exposure to one antibiotic increases the susceptibility to a different one ([@B64]; [@B35]). This might be achieved through two mechanisms. One possible mechanism is that exposure to one antibiotic directly causes increased susceptibility to a different one, for example, mutations in the β-lactamase AmpC increases cephalosporin hydrolysis while reducing that of penicillins or carbapenems ([@B8]). The second possibility is that the development of a resistance mechanism impairs the activity of another existing resistance mechanism. An example is competition between the different efflux pumps, since the overexpression of one may impair the expression of another ([@B58]). Thus, the evolution of the mutational resistome for a given antibiotic is not only dependent on the exposure to this antibiotic, but it is also conditioned by the simultaneous or even previous exposures to other antibiotics. An illustrative example is provided in a recent *in vitro* study that demonstrated, for a broad range of antibiotic classes, that the history of exposure and resistance development to a given antibiotic, conditions the dynamics and mechanisms of resistance development when exposed to a second one ([@B74]). In summary, the comprehensive analysis of the mutational resistome of *P. aeruginosa* in CF and nosocomial infections is expected to become a useful tool for optimizing therapeutic strategies and monitoring the efficacy of administered antibiotic treatments in the near future.
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